A new type of weight-loss drug taken as a pill rather than an injection cut deaths by 57% over two years in a large diabetes trial, compared to standard insulin therapy.
The drug is called orforglipron (Lilly markets it as Foundayo for obesity). It works on the same biological target as Ozempic, Wegovy, and Mounjaro, the GLP-1 receptor, but it is the first drug in the class that is a small chemical molecule rather than a peptide. That distinction matters more than it sounds.
What "first pill" actually means
The current Ozempic-class drugs are peptides, which are long chains of amino acids. Peptides are fragile in the human digestive system; they get broken down in the stomach before they can be absorbed. That is why all of them have been injected weekly with a pen device that most patients keep in a refrigerator. It is also why they are expensive: peptide manufacturing is more complex than small-molecule pill manufacturing.
Orforglipron is a small molecule. It survives digestion, crosses the gut wall, reaches the bloodstream, and activates the GLP-1 receptor from a different direction than the peptide drugs do. In practical terms, that means a daily tablet with no food or water timing requirements and no cold-chain storage. It also means the manufacturing cost is lower.
The trial
ACHIEVE-4 enrolled 2,749 adults with type 2 diabetes across 15 countries and ran for 104 weeks (two years). Participants were randomized to orforglipron or insulin glargine, a widely-used standard treatment for type 2 diabetes.
The headline finding was a 57% reduction in all-cause deaths (technical form: HR 0.43, p=0.002) compared to insulin. Participants on orforglipron also lost about 10 percentage points more body weight at one year. The primary heart-safety endpoint was met.
Why the mortality finding matters
Weight-loss drugs in this class have been shown to extend life before. The SELECT trial of semaglutide, for instance, showed a cardiovascular benefit. But that trial compared the drug to a sugar pill (placebo). Showing the same kind of benefit against an actual standard treatment like insulin is a higher bar, because you are not just beating "nothing," you are beating "what most diabetic patients already take." ACHIEVE-4 cleared that bar.
What this piece is not claiming
It is not saying peptide versions of the class are obsolete. ACHIEVE-4 did not compare orforglipron against semaglutide directly. That head-to-head comparison has not been run. And a separate FDA request for additional post-market liver and heart safety data on Foundayo ↗ suggests regulators are not treating this trial as the last word on long-term safety.
What to watch next
Lilly plans to submit the full trial package to the FDA by the end of this quarter. The submission covers more than 11,000 patients across seven studies. ACHIEVE-4 is the cardiovascular anchor of that package. Approval for type 2 diabetes is likely this year. Broader obesity approval is a separate regulatory path.
Pricing is the other open question. Orforglipron's manufacturing cost is lower than the peptide drugs, which creates room for more aggressive pricing. Whether Lilly uses that room depends on how it competes with Novo Nordisk's (semaglutide's) pricing, and how the broader commercial environment for weight-loss drugs shifts.
What we host
Our GLP-1 receptor page ↗ catalogs 204 peptide candidates aimed at the same biological target orforglipron activates. What this trial tells anyone designing a new molecule against that target is that the benefit is coming from the target itself, not from peptide-specific chemistry, so the target is validated at the highest clinical bar available. The remaining molecular design questions (half-life, oral bioavailability for peptides that try to match the pill advantage, muscle preservation, stomach tolerance) are now sharper, not looser.